Mikhail Blagosklonny’s Influence in Oncology and the Subject of Aging

Though organ transplant surgery is much more reliable now than in past years there is still a chance of rejection. Luckily the drug Rapamycin aka Sirolimus exists. It is used to prevent the body from rejecting a transplanted organ. The drug is also flexible capable of treating rare lung diseases too. Though it was created to treat a multitude of health issues it is most known as a cancer drug.

The first ever use of this wonder drug was as an anti-fungal agent. Eventually researchers discovered that what made the drug truly special was its immunosuppressive and antiproliferative properties. After this discovery Rapamycin was no longer used by doctors as an anti-fungal agent. Read more on templeofthecave.com.

Individuals like Mikhail Blagosklonny have done extensive research involving oncology. He has been doing so for a number of years and is currently the professor of Oncology at the Roswell Park Cancer Institute. He also serves as Editor-in-Chief of Oncotarget, a bi-weekly bio-medical journal dedicated to providing all information regarding oncology. He is an avid supporter of the use of Rapamycin. He believes the drug has the potential to slow the aging process an extend an individuals life span. It is a bold statement, but he is the leading researcher on the subject of aging.

To name all the reasons Rapamycin is one of the best medicines on the market would take forever. With that being said, all it takes is a little research to realize why this drug is so wonderful.

Mikhail Blagosklonny is often asked about his plans for oncology. Though he may not have a definitive answer his research tells a story. Something he is very interested in is the relationship between cancer and aging. We all know that cancer is more common in older individuals but we don’t exactly know why. He continually conducts research in the hopes of finding the answer. Visit classroomvoices.org to read more about Mikhail.

What Mikhail chooses to research as it pertains to cancer always turns heads within the medical field. Of course his ultimate goal is fining a cure for cancer, but in the short term he wants to substantially improve cancer treatment so it is no longer torturous to the average patient. He hopes in the near future that top of the line cancer treatment will be significantly more affordable and available for all.

Read: http://www.phillypurge.com/2017/07/14/oncotarget-mikhail-blagosklonny-rapamycin-incredible-healing-properties/